Wegovy helped patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass, while the combination of Regeneron's trevogrumab and Wegovy led to weight loss of about ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Several pharmaceutical companies are developing novel weight-loss drugs that focus not just on reducing fat but also on ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual GLP-1/GIP receptor agonist in a deal worth $2bn. The in-licensing agreement will ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

June 2 (Reuters) - Regeneron (REGN.O), opens new ... the highest rate among all groups tested in the study. "Incremental improved weight loss from double and triple therapy are promising," said ...